Docon Technologies Private Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Docon Technologies, the promoter of Thyrocare Technologies with a 71.06% stake (3.76 crore shares), has filed its annual disclosure under SEBI's Takeover Code confirming that no new encumbrances (pledges) were created on Thyrocare shares during FY ended March 31, 2025. The entire 71.06% promoter shareholding remains pledged/encumbered — originally created in June 2022 and modified several times since, with the latest modification on June 14, 2024. The slight drop in encumbrance percentage from 71.18% to 71.06% is due to expansion of total share capital, not any release of pledged shares. There were no releases, invocations, or new creations during FY25.
This is a routine annual compliance filing, but it highlights a significant ongoing risk: nearly the entire promoter stake (71%) is pledged, meaning any margin call or loan default could trigger a forced sale and put heavy selling pressure on the stock. Investors should monitor for any future pledge releases or modifications.